Abstract | BACKGROUND & AIMS: METHODS: RESULTS: Median age was 47 years and follow-up period was 2.4 years, with 403, 281, 165, and 73 patients followed-up for at least 1, 2, 3, and 4 years, respectively. Incremental increases were observed in the rates of undetectable HBV DNA, HBeAg seroclearance and seroconversion, and ALT normalization, reaching 96%, 42%, 38% and 93%, respectively, by the fourth year. In all, 100% and 93% of patients negative and positive for HBeAg, respectively, had undetectable HBV DNA at year 4. Of 165 patients, HBV DNA was detectable in nine patients after 3 years. Multivariate analysis identified HBV DNA level (≤7.6 log(10) copies/ml, OR=15.8; 95% CI=43.1-79.9, P=0.001) as an independent predictor of undetectable HBV DNA at year 3. Five patients experienced virological breakthrough including two (0.4%) who developed entecavir-resistance mutations. CONCLUSIONS: Continuous treatment of nucleos(t)ide-naïve CHB patients with entecavir over 4 years was associated with 96% chance of undetectable HBV DNA and only 0.4% chance of emerging entecavir-resistant mutations.
|
Authors | Atsushi Ono, Fumitaka Suzuki, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitou, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Sachiyo Watahiki, Rie Mineta, Hiromitsu Kumada |
Journal | Journal of hepatology
(J Hepatol)
Vol. 57
Issue 3
Pg. 508-14
(Sep 2012)
ISSN: 1600-0641 [Electronic] Netherlands |
PMID | 22659518
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Antiviral Agents
- DNA, Viral
- Hepatitis B e Antigens
- entecavir
- Guanine
- Alanine Transaminase
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Alanine Transaminase
(blood)
- Antiviral Agents
(therapeutic use)
- Confidence Intervals
- DNA, Viral
(blood)
- Drug Resistance, Viral
- Female
- Genotype
- Guanine
(analogs & derivatives, therapeutic use)
- Hepatitis B e Antigens
(blood)
- Hepatitis B virus
(genetics)
- Hepatitis B, Chronic
(blood, drug therapy)
- Humans
- Kaplan-Meier Estimate
- Longitudinal Studies
- Male
- Middle Aged
- Multivariate Analysis
- Mutation
- Odds Ratio
- Retrospective Studies
- Time Factors
- Young Adult
|